[1]陈慈民,张雨,陈美玲,等.木犀草素与青蒿琥酯联合用药防治实验性外伤性增生性玻璃体视网膜病变[J].眼科新进展,2023,43(9):680-685.[doi:10.13389/j.cnki.rao.2023.0137]
　CHEN Cimin,ZHANG Yu,CHEN Meiling,et al.Prevention and treatment of experimental traumatic proliferative vitreoretinopathy with luteolin and artesunate[J].Recent Advances in Ophthalmology,2023,43(9):680-685.[doi:10.13389/j.cnki.rao.2023.0137]
点击复制

木犀草素与青蒿琥酯联合用药防治实验性外伤性增生性玻璃体视网膜病变/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
43卷
期数:
2023年9期
页码:
680-685
栏目:
实验研究
出版日期:
2023-09-05

文章信息/Info

Title:
Prevention and treatment of experimental traumatic proliferative vitreoretinopathy with luteolin and artesunate
作者:
陈慈民; 张雨; 陈美玲; 徐柒华
330006　江西省南昌市，南昌大学附属眼科医院
Author(s):
CHEN Cimin; ZHANG Yu; CHEN Meiling; XU Qihua
Ophthalmology Hospital Affiliated Nanchang University,Nanchang 330006,Jiangxi Province,China
关键词:
木犀草素; 青蒿琥酯; 联合用药; 上皮间充质转化; 外伤性增生性玻璃体视网膜病变
Keywords:
luteolin;  artesunate;  drug combination;  epithelial-mesenchymal transition;  traumatic proliferative vitreoretinopathy
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2023.0137
文献标志码:
A
摘要:
目的　探讨木犀草素（LU）与青蒿琥酯（ART）联合用药在外伤性增生性玻璃体视网膜病变（TPVR）中的作用。
方法　选取16只月龄、体重相近的健康成年雄性青紫蓝兔，实验眼（右眼）玻璃体内注射富含血小板血浆0.3 mL制作TPVR模型。将实验兔随机分成4组，每组4只，对照组玻璃体内注射0.2 mL生理盐水；单用药物组分别在玻璃体内注射0.2 mL的LU（LU组）及0.2 mL的ART（ART组），联合用药组（联合组）玻璃体内注射LU及ART各0.1 mL。注药后第4周通过眼部B超及眼底照相检查观察玻璃体混浊情况及视网膜改变情况并划分相对应的增生性玻璃体视网膜病变（PVR）等级；取眼球组织行Western blot实验检测各组α平滑肌肌动蛋白（α-SMA）表达水平，制作眼球组织切片行HE染色观察结构改变。PVR分级等级资料比较采用秩和检验；多组间比较采用单因素方差分析，组间差异比较使用Bonferroni检验。
结果　眼部B超及眼底照相检查观察结果提示，ART组、LU组及联合组兔玻璃体改变均优于对照组。ART组、LU组、联合组PVR分级均优于对照组，差异均有统计学意义（均为P<0.05）。Western blot检测结果显示，联合组兔玻璃体内α-SMA表达水平最低；联合组、ART组、LU组α-SMA表达水平均低于对照组，差异均有统计学意义（均为P<0.05）；其中，联合组α-SMA与LU组比较，差异有统计学意义（P<0.05），联合组α-SMA与ART组比较，差异无统计学意义（P>0.05）。HE染色结果显示，对照组视网膜脱离、水肿最严重，联合组兔视网膜浅脱离，结构大体平整，损伤轻于ART组及LU组。
结论　玻璃体内注射LU、ART的联合用药可有效抑制实验动物模型TPVR的发展，优于LU、ART的单用治疗效果。未来应进一步研究联合用药的具体协同机制，为治疗TPVR的研究打下基础。
Abstract:
Objective　To investigate the effect of luteolin (LU) and artesunate (ART) in the treatment of traumatic proliferative vitreoretinopathy (TPVR).
Methods　TPVR models were established by injecting 0.3 mL of platelet-rich plasma into the vitreous cavity of the experimental eyes (right eyes) of 16 healthy adult blue rabbits of a similar weight and age. The experimental rabbits were randomly divided into 4 groups, with 4 rabbits in each group. Those in the control group were intravitreally injected with 0.2 mL of normal saline; those in the LU group were intravitreally injected with 0.2 mL of LU; those in the ART group were intravitreally injected with 0.2 mL of ART; and those in the combination group were intravitreally injected with 0.1 mL of LU and ART, respectively. At the 4th week after injection, the vitreous opacity and retinal changes were recorded with the aid of an ophthalmic B-scan ultrasound device and a fundus camera, and proliferative vitreoretinopathy (PVR) grades were determined. Eyeball tissues were removed for Western blotting to measure the expression level of α smooth muscle actin (α-SMA). Eyeball slices were stained with hematoxylin & eosin (HE) to survey structural changes. PVR grading data were compared using the rank sum test. Multi-group comparisons were conducted using the one-way analysis of variance. Differences among groups were analyzed using the Bonferroni test.
Results　The observations under the ophthalmic B-scan ultrasound device and fundus camera showed that changes in the vitreous cavity in the ART, LU, and combination groups were better than those in the control group. The PVR grading in the ART, LU, and combination groups was superior to that in the control group, and the differences were statistically significant (all P<0.05). Western blot results showed that the α-SMA level in the ART, LU, and combination groups was lower than that in the control group (all P<0.05) and the lowest in the combination group, and the difference between the combination group and the LU group was statistically significant (P<0.05) but not significant between the combination group and the ART group (P>0.05). The HE staining results showed that the retinal detachment and edema in the control group were the most serious, while the retinal detachment in the combination group was shallow, the structure was generally flat, and the damage was milder than that in the ART and LU groups.
Conclusion　Intravitreal injection of both LU and ART can effectively inhibit the development of TPVR in experimental animal models, which is superior to the efficacy of LU and ART alone. Further research needs to be conducted on the synergistic mechanisms of the drug combination to lay the foundation for the treatment of TPVR.

参考文献/References:

［1］　张琼,陈松.外伤性增生性玻璃体视网膜病变防治的研究进展［J］.国际眼科纵览,2015,39(1):60-64.
ZHANG Q,CHEN S.Progress in prevention and treatment of traumatic proliferative vitreoretinopathy［J］.Int Rev Ophthalmol,2015,39(1):60-64.
［2］　ORBAN M,ISLAM Y F K,HADDOCK L J.Timing and outcomes of vitreoretinal surgery after traumatic retinal detachment［J］.J Ophthalmol,2016,2016:4978973.
［3］　郭海霞,于金国,颜华.曲安奈德在增生性玻璃体视网膜病变中应用的研究进展［J］.眼科新进展,2021,41(10):992-995,1000.
GUO H X,YU J G,YAN H.Progress of triamcinolone acetonide in the treatment of proliferative vitreo-retinopathy［J］.Rec Adv Ophthalmol,2021,41(10):992-995,1000.
［4］　HAMDY GHORABA H,LEILA M,ELGOUHARY S M,ELGEMAI E E M,ABDELFATTAH H M,GHORABA H H,et al.Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries［J］.Clin Ophthalmol,2018,12:2383-2391.
［5］　HYTTI M,PIIPPO N,KORHONEN E,HONKAKOSKI P,KAARNIRANTA K,KAUPPINEN A.Fisetin and luteolin protect human retinal pigment epithelial cells from oxidative stress-induced cell death and regulate inflammation［J］.Sci Rep,2015,5:17645.
［6］　WANG X Q,LIU H L,WANG G B,WU P F,YAN T,XIE J,et al.Effect of artesunate on endotoxin-induced uveitis in rats［J］.Invest Ophthalmol Vis Sci,2011,52(2):916.
［7］　CHENG R,LI C,LI C,WEI L,LI L,ZHANG Y,et al.The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells［J］.Invest Ophthalmol Vis Sci,2013,54(5):3400.
［8］　DENSTEDT J,SCHULZ D C,DIACONITA V,SHEIDOW T G.Acupuncture resulting in eye penetration and proliferative vitreoretinopathy-Surgical and medical management with intraocular methotrexate［J］.Am J Ophthalmol Case Rep,2020,18:100605.
［9］　WIEDEMANN P,LEMMEN K,SCHMIEDL R,HEIMANN K.Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy［J］.Am J Ophthalmol,1987,104(1):10-14.
［10］　KHANUM B K,GUHA R,SUR V P,NANDI S,BASAK S K,KONAR A,et al.Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy［J］.Eye,2017,31(9):1317-1328.
［11］　WANG H F,MA J X,SHANG Q L,AN J B,CHEN H T.Crocetin inhibits the proliferation,migration and TGF-β2-induced epithelial-mesenchymal transition of retinal pigment epithelial cells［J］.Eur J Pharmacol,2017,815:391-398.
［12］　刘丽娅,马景学,安建斌,刘丹岩,高彦军,周娜磊,等.姜黄素、丹参单体和苦参碱抑制IL-1β诱导下兔RPE细细胞增生的体外实验研究［J］.中华实验眼科杂志,2016,34(8):699-704.
LIU L Y,MA J X,AN J B,LIU D Y,GAO Y J,ZHOU N L,et al.Inhibitory effect of curcumin,salvia miltiorrhiza and matrine on IL-1β-induced proliferation of rabbit RPE cells in vitro［J］.Chin J Exp Ophthalmol,2016,34(8):699-704.
［13］　ER H,TURKOZ Y,MZRAK B,PARLAKPNAR H.Inhibition of experimental proliferative vitreoretinopathy with protein kinase C inhibitor (chelerythrine chloride) and melatonin［J］.Ophthalmologica,2005,220(1):17-22.
［14］　CARDILLO J A,FARAH M E,MITRE J,MORALES P H,COSTA R A,MELO L A S,et al.An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy［J］.Br J Ophthalmol,2004,88(9):1201-1205.
［15］　SALAH-ELDIN M,PEYMAN G A,EL-ASWAD M,BANDOK B,BAHGAT M M,NIESMAN M R.Evaluation of toxicity and efficacy of a combination of antineoplastic agents in the prevention of PVR［J］.Int Ophthalmol,1994,18(2):53-60.
［16］　陈洁,吴灵丹,王资懿,徐柒华.三种方法建立外伤性增生性玻璃体视网膜病变的兔模型研究［J］.中国病理生理杂志,2022,38(5):954-960.
CHEN J,WU L D,WANG Z Y,XU Q H.Establishment of a rabbit model of traumatic proliferative vitreoretinopathy using three methods［J］.Chin J Pathophysiol,2022,38(5):954-960.
［17］　吴灵丹,陈洁,王资懿,徐柒华.三种药物在兔外伤性增生性玻璃体视网膜病变中的作用［J］.国际眼科杂志,2022,22(6):920-925.
WU L D,CHEN J,WANG Z Y,XU Q H.Role of three drugs in traumatic proliferative vitreoretinopathy in rabbits［J］.Int Eye Sci,2022,22(6):920-925.
［18］　HILTON G,MACHEMER R,MICHELS R,OKUN E,SCHEPENS C,SCHWARTZ A.The classification of retinal detachment with proliferative vitreoretinopathy［J］.Ophthalmology,1983,90(2):121-125.
［19］　林树燕,吴志群,吴庆伟,蔡隆生,曾炎.195例眼外伤住院患者的受伤原因和临床分析［J］.伤害医学(电子版),2021,10(3):11-14.
LIN S Y,WU Z Q,WU Q W,CAI L S,ZENG Y.Causes of injury and clinical analysis of 195 patients with ocular trauma［J］.Inj Med(Electron Edit),2021,10(3):11-14.
［20］　路永珩,郑轶.增生性玻璃体视网膜病变发病机制与治疗的研究进展［J］.医学综述,2018,24(13):2548-2552,2558.
LU Y H,ZHENG Y.Research progress of pathogenesis and treatment of proliferative vitreoretinopathy［J］.Med Recap,2018,24(13):2548-2552,2558.
［21］　CARDILLO J A,STOUT J T,LABREE L,AZEN S P,OMPHROY L,CUI J Z,et al.Post-traumatic proliferative vitreoretinopathy.The epidemiologic profile,onset,risk factors,and visual outcome［J］.Ophthalmology,1997,104(7):1166-1173.
［22］　WELLER M,WIEDEMANN P,HEIMANN K.Proliferative vitreoretinopathy--is it anything more than wound healing at the wrong place?［J］.Int Ophthalmol,1990,14(2):105-117.
［23］　SHU D Y,LOVICU F J.Myofibroblast transdifferentiation:the dark force in ocular wound healing and fibrosis［J］.Prog Retin Eye Res,2017,60:44-65.
［24］　WELLER M,HEIMANN K,WIEDEMANN P.Immunochemical studies of epiretinal membranes using APAAP complexes:evidence for macrophage involvement in traumatic proliferative vitreoretinopathy［J］.Int Ophthalmol,1988,11(3):181-186.
［25］　张悦,刘含若.Müller细胞在视网膜疾病发病机制中的作用［J］.国际眼科纵览,2022,46(2):179-184.
ZHANG Y,LIU H R.Role of Müller cells in pathogenesis of retinal diseases［J］.Int Rev Ophthalmol,2022,46(2):179-184.
［26］　CHIBA C.The retinal pigment epithelium:an important player of retinal disorders and regeneration［J］.Exp Eye Res,2014,123:107-114.
［27］　胡可可,杜红俊,惠延年.血管内皮生长因子及上皮-间充质转化在增生性玻璃体视网膜病变发病中的作用［J］.国际眼科杂志,2022,22(6):969-972.
HU K K,DU H J,HUI Y N.Role of vascular endothelial growth factor and epithelial-mesenchymal transition in the vitreoretinopathy［J］.Int Eye Sci,2022,22(6):969-972.
［28］　ZHANG W,LI J.Yes-associated protein is essential for proliferative vitreoretinopathy development via the epithelial-mesenchymal transition in retinal pigment epithelial fibrosis［J］.J Cell Mol Med,2021,25(21):10213-10223.
［29］　ZHOU Q,XU G,ZHANG X,CAO C,ZHOU Z.Proteomics of post-traumatic proliferative vitreoretinopathy in rabbit retina reveals alterations to a variety of functional proteins［J］.Curr Eye Res,2012,37(4):318-326.
［30］　TELANDER D G,YU A K,FORWARD K I,MORALES S A,MORSE L S,PARK S S,et al.Epithelial membrane protein-2 in human proliferative vitreoretinopathy and epiretinal membranes［J］.Invest Ophthalmol Vis Sci,2016,57(7):3112-3117.
［31］　余进海,刘琪,廖洪斐,徐柒华.增生性玻璃体视网膜病变中调控上皮间质转化的研究进展［J］.眼科新进展,2019,39(10):992-995.
YU J H,LIU Q,LIAO H F,XU Q H.Advances in the regulation of epithelial-mesenchymal transition in Proliferative vitreoretinopathy［J］.Rec Adv Ophthalmol,2019,39(10):992-995.
［32］　ISHIKAWA K,HE S,TERASAKI H,NAZARI H,ZHANG H,SPEE C,et al.Resveratrol inhibits epithelial-mesenchymal transition of retinal pigment epithelium and development of proliferative vitreoretinopathy［J］.Sci Rep,2015,5:16386.
［33］　何建锋,吕立夏,罗俊杰,李宗义,沈俊慧,徐国彤,等.Src激酶抑制剂CGP77675对TGF-β1诱导的视网膜色素上皮细胞上皮-间质转化的抑制作用［J］.中华实验眼科杂志,2018,36(1):5-11.
HE J F,LYU L X,LUO J J,LI Z Y,SHEN J H,XU G T,et al.Inhibiting effects of Src kinase inhibitor on TGF-β1 induced epithelial-mesenchymal transition of human RPE cells［J］.Chin J Exp Ophthalmol,2018,36(1):5-11.
［34］　WANG Z Y,ZHANG Y,CHEN J,WU L D,CHEN M L,CHEN C M,et al.Artesunate inhibits the development of PVR by suppressing the TGF-β/Smad signaling pathway［J］.Exp Eye Res,2021,213:108859.
［35］　WANG Z Y,WU L D,CHEN J,CHEN M L,CHEN C M,XU Q H,et al.Artesunate inhibits proliferation and migration of RPE cells and TGF-β2 mediated epithelial mesenchymal transition by suppressing PI3K/AKT pathway［J］.Int J Ophthalmol,2022,15(2):197-204.
［36］　CHEN L,ZHU Y,ZHOU J,WU R,YANG N,BAO Q,et al.Luteolin alleviates epithelial-mesenchymal transformation induced by oxidative injury in ARPE-19 cell via Nrf2 and AKT/GSK-3β pathway［J］.Oxid Med Cell Longev,2022,2022:2265725.

相似文献/References:

[1]陈静,陈艺,邹秀兰,等.青蒿琥酯对人Tenon囊成纤维细胞增殖与凋亡的影响[J].眼科新进展,2017,37(6):523.[doi:10.13389/j.cnki.rao.2017.0132]
　CHEN Jing,CHEN Yi,ZOU Xiu-Lan,et al.Effects of artesunate on cell proliferation and apoptosis of human Tenon’s capsule fibroblasts[J].Recent Advances in Ophthalmology,2017,37(9):523.[doi:10.13389/j.cnki.rao.2017.0132]
[2]魏达亨,孙丽丽,何慧君,等.木犀草素对碘酸钠诱导的视网膜色素上皮细胞及视网膜损伤的保护作用[J].眼科新进展,2019,39(9):814.[doi:10.13389/j.cnki.rao.2019.0185]
　WEI Da-Heng,SUN Li-Li,HE Hui-Jun,et al.Protective effect of luteolin against damage to retinal pigment epithelial cells and retina induced by sodium iodate[J].Recent Advances in Ophthalmology,2019,39(9):814.[doi:10.13389/j.cnki.rao.2019.0185]
[3]史梦琳,吴玮琪,罗昊,等.木犀草素对人脉络膜黑色素瘤细胞株C918血管生成拟态形成的影响[J].眼科新进展,2020,40(8):731.[doi:10.13389/j.cnki.rao.2020.0166]
　SHI Menglin,WU Weiqi,LUO Hao,et al.Inhibitory effects of luteolin on vasculogenic mimicry in human choroidal melanoma cell line C918[J].Recent Advances in Ophthalmology,2020,40(9):731.[doi:10.13389/j.cnki.rao.2020.0166]
[4]李茜,王红星,傅强,等.木犀草素对视网膜缺血-再灌注损伤(RIRI)大鼠TLR4/Syk/NF-κB信号通路及视网膜的影响[J].眼科新进展,2021,41(4):311.[doi:10.13389/j.cnki.rao.2021.0065]
　LI Qian,WANG Hongxing,FU Qiang,et al.Effects of luteolin on TLR4/Syk/NF-κB signaling pathway and retina in rats with retinal ischemia-reperfusion injury[J].Recent Advances in Ophthalmology,2021,41(9):311.[doi:10.13389/j.cnki.rao.2021.0065]
[5]陆秉文,胥静,谢立科,等.青蒿琥酯对大鼠实验性视网膜分支静脉阻塞的抑制作用[J].眼科新进展,2022,42(11):853.[doi:10.13389/j.cnki.rao.2022.0176]
　LU Bingwen,XU Jing,XIE Like,et al.Inhibitory effect of artesunate on experimental branch retinal vein occlusion in rats[J].Recent Advances in Ophthalmology,2022,42(9):853.[doi:10.13389/j.cnki.rao.2022.0176]

备注/Memo

备注/Memo:
国家自然科学基金（编号：82260210）；江西省卫生健康委科技计划项目（编号：202210048）；江西省重点研发计划项目一般项目（编号：20202BBG73023）；江西省中医药科技计划一般项目（编号：2021B667）
更新日期/Last Update: 2023-09-05